BMS and Calithera Announce Clinical Collaboration to Evaluate nivolumab in combination with CB-839 for Renal Cell Carcinoma

December 21, 2016 Bristol-Myers Squibb Company and Calithera Biosciences, Inc., a clinical stage biotechnology company focused on discovering and developing new small molecule drugs directed against tumor metabolism and tumor immunology targets for treating cancer, have announced a clinical trial collaboration to evaluate the Opdivo of Bristol-Myers Squibb in combination with  CB-839 of Calithera in patients with … Continue reading BMS and Calithera Announce Clinical Collaboration to Evaluate nivolumab in combination with CB-839 for Renal Cell Carcinoma

Advertisements
Igeahub.com - Top Pharma News - Luca Dezzani

Top Pharma News – November 2016

New Research Details Published by Merck Scientists About the Early Development of Verubecestat November 2, 2016 Merck has announced the publication of research conducted by Merck scientists on the discovery and development of verubecestat. It is an investigational small molecule inhibitor of the enzyme beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), which is used … Continue reading Top Pharma News – November 2016

BMS logo

Opdivo (nivolumab) and Yervoy (ipilimumab) Regimen Shows Promising Safety and Efficacy in Previously Treated Patients with Advanced Form of Bladder Cancer

November 12, 2016 Bristol-Myers Squibb Company has announced positive results from the Phase 1/2 open-label CheckMate-032 trial that investigates two combination schedules of Opdivo (nivolumab) plus Yervoy (ipilimumab) in patients with locally advanced or metastatic urothelial carcinoma (mUC) previously treated with platinum-based therapy. These data were presented during the Oral Late-breaking Abstract Session II, at the 31st Annual Meeting and Associated … Continue reading Opdivo (nivolumab) and Yervoy (ipilimumab) Regimen Shows Promising Safety and Efficacy in Previously Treated Patients with Advanced Form of Bladder Cancer

Igeahub.com - Top Pharma News - Luca Dezzani

Pharma Oncology | Top News – Fall 2016

AbbVie and Bristol-Myers Squibb Collaborate to Evaluate the Combination of Rova-T plus Opdivo and Opdivo + Yervoy Regimen July 25, 2016 AbbVie and Bristol-Myers Squibb Company have announced a clinical trial collaboration for evaluating the safety, efficacy, and tolerability of investigational biomarker-specific antibody drug conjugate Rova-T (rovalpituuzumab tesirine) of AbbVie in combination with Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen … Continue reading Pharma Oncology | Top News – Fall 2016

ESMO - Igea - Luca Dezzani

Top News from ESMO 2016

 Immune checkpoint inhibitors for urothelial cancer: New hope with new options 11 Oct 2016 Platinum-based chemotherapy has been the mainstay of treatment for urothelial cancer; however, targeted biologics are now gaining prominence in this setting. Programmed death-1 (PD-1/PD-L1) checkpoint inhibitors facilitate tumour infiltration by T cells, resulting in targeted destruction by the immune system. Advancing … Continue reading Top News from ESMO 2016

Bristol-Myers Squibb Collaborates with Janssen in Immuno-Oncology Research Focused on Lung Cancer

July 26, 2016 Bristol-Myers Squibb Company has announced a new clinical research collaboration with Janssen Biotech, Inc. to evaluate Bristol-Myers Squibb’s Immuno-Oncology (I-O) agent Opdivo (nivolumab) and Janssen’s Live Attenuated Double–Deleted (LADD) Listerial monocytogenes cancer immunotherapy, expressing mesothelin and EGFRvIII (JNJ-64041757), in patients with non-small cell lung cancer (NSCLC). Opdivo is a human antibody that is used for alleviating immune suppression. … Continue reading Bristol-Myers Squibb Collaborates with Janssen in Immuno-Oncology Research Focused on Lung Cancer

AbbVie and Bristol-Myers Squibb Collaborate to Evaluate the Combination of Rova-T plus Opdivo and Opdivo + Yervoy Regimen

July 25, 2016 AbbVie and Bristol-Myers Squibb Company have announced a clinical trial collaboration for evaluating the safety, efficacy, and tolerability of investigational biomarker-specific antibody drug conjugate Rova-T (rovalpituuzumab tesirine) of AbbVie in combination with Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen of Bristol-Myers Squibb as a treatment for relapsed extensive-stage small cell lung cancer (SCLC). “We believe the combination … Continue reading AbbVie and Bristol-Myers Squibb Collaborate to Evaluate the Combination of Rova-T plus Opdivo and Opdivo + Yervoy Regimen

Bristol-Myers Squibb and PsiOxus Therapeutics Declare Immuno-Oncology Clinical Collaboration to Evaluate the Combination of Opdivo and Enadenotucirev

June 30, 2016 Bristol-Myers Squibb Company and PsiOxus Therapeutics, Ltd. have announced an exclusive clinical collaboration agreement for evaluating the tolerability, safety, and preliminary efficacy of Bristol-Myers Squibb’s Immuno-Oncology (I-O) agent Opdivo (nivolumab), in combination with PsiOxus’ enadenotucirev, a systemically administered oncolytic adenovirus therapeutic, to treat a range of tumor types in late-stage cancer patients. “This collaboration continues … Continue reading Bristol-Myers Squibb and PsiOxus Therapeutics Declare Immuno-Oncology Clinical Collaboration to Evaluate the Combination of Opdivo and Enadenotucirev

Igeahub.com - Top Pharma News - Luca Dezzani

Top Pharma News – June 2016

Astellas and Seattle Genetics Present ASG-15ME and ASG-22ME Phase I Clinical Data in Metastatic Urothelial Cancer June 6, 2016 Astellas Pharma Inc. and Seattle Genetics, Inc. (NASDAQ: SGEN) have presented first clinical data for ASG-15ME and ASG-22ME at the American Society of Clinical Oncology (ASCO) 51st Annual Meeting that was held in June 3-7, 2016 in Chicago, IL.   … Continue reading Top Pharma News – June 2016

Igeahub.com - Top Pharma News - Luca Dezzani

Pharma Oncology | Top News – Spring 2016

GSK Returns to War against Cancer April 3, 2016 It looked like the UK pharmaceuticals group GlaxoSmithKline (GSK) was declaring surrender in the war on cancer when the company agreed to sell its oncology drugs for $16 billion to Novartis in 2014. However, after two years, GSK returns to this war on cancer again.   … Continue reading Pharma Oncology | Top News – Spring 2016